Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bedini, A. V.
Right arrow Articles by Ravasi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bedini, A. V.
Right arrow Articles by Ravasi, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 6:838-840, 1995
© 1995 European Society for Medical Oncology

research-article

Ambulatory low-toxicity chemotherapy in non-small-cell lung carcinoma by continuous 28-day infusion of alternating cisplatin and 5-fluorouracil

A. V. Bedini, L. Tavecchio, C. Lequaglie and G. Ravasi

National Cancer Institute Milan, Italy

Correspondence to: Amedeo V. Bedini, M.D. Divisione OCT Istituto Nazionale Tumori Via G. Venezian 1 20133 Milan, Italy

Background: One regimen consisting of a continuous infusion of cisplatin and fluorouracil was designed to be minimally toxic, and suitable for application with radiotherapy in non-small-cell lung carcinoma (NSCLC)

Patients and methods: Forty-four NSCLC patients received daily 8 mg/m2 of cisplatin on days 1–2, 8–9, 15–16, 22–23, and 300 mg/m2 of fluorouracil on days 3–7, 10–14, 17–21, 24–28 (35-day courses)

Results: Two patients experienced grade 3–4 toxicities. Eleven achieved objective responses. The median progression-free and observed survival was 22 and 39.5 weeks

Conclusions: The schedule management was fully ambulatory. Toxicity was negligible. The activity was moderate, but the combination with radiotherapy is advisable due to the radioenhancing properties of both of the drugs

cisplatin, continuous infusion, fluorouracil, lung cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.